MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.210
-0.020
-1.63%
Closed 17:11 12/26 EST
OPEN
1.230
PREV CLOSE
1.230
HIGH
1.235
LOW
1.190
VOLUME
511.43K
TURNOVER
--
52 WEEK HIGH
14.26
52 WEEK LOW
1.100
MARKET CAP
74.35M
P/E (TTM)
-0.4219
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (1222-1226)?
Weekly Report · 12m ago
Pliant Therapeutics Files Initial Beneficial Ownership Statement for Chief Operating Officer Minnie Kuo
Reuters · 6d ago
Weekly Report: what happened at PLRX last week (1215-1219)?
Weekly Report · 12/22 10:14
Pliant Therapeutics Appoints Minnie Kuo as COO
TipRanks · 12/16 22:34
Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer
Reuters · 12/16 22:06
Weekly Report: what happened at PLRX last week (1208-1212)?
Weekly Report · 12/15 10:20
Pliant Therapeutics Announces Departure of Chief Medical Officer
TipRanks · 12/08 21:56
PLIANT THERAPEUTICS INC - TERMINATES CMO ÉRIC LEFEBVRE EFFECTIVE DECEMBER 15 - SEC FILING
Reuters · 12/08 21:42
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.